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Figure S1: Sensitivity of high and low multiplicity cell-free virus infection to TFV. 
MT-4 cells were either mock infected with growth medium (top row), or infected with 
fluorescently labeled HIV (YFPNL4-3) at high m (middle row) or low m (bottom row). 
Cells were pre-incubated for 24 hours with TFV and infected in the presence of the 
drug at the concentrations shown above the plots. Two days after infection, 2x105 MT-
4 cells were analyzed by flow cytometry for YFP fluorescence. Gated cells had a high 
535nm (YFP specific fluorescence) to 590nm (auto-fluorescence) ratio. Numbers 
above gate are the percent of YFP positive cells in the total population.
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Figure S2: Time to GFP expression in HIV infected Rev-CEM reporter cells. The 
length of a full viral cycle was approximated by the time to Tat and Rev dependent 
GFP expression. At time 0, infected MT-4mCherry cells were added to uninfected 
Rev-CEM cells and infection imaged with time-lapse microscopy at 37ºC with 5% 
CO2 for a period of 58 hours. a) Appearance of GFP in a Rev-CEM reporter cell 
(green). Time in hours indicated in top right corner. Red cell is infected MT-
4mCherry donor. Scale bar is 20 μm. b) histogram of GFP expression times in 144 
Rev-CEM cells. Fusions between donors and targets were excluded from analysis. 
Red curve represents fit of normal distribution with a mean = 40 hours and s.d. = 9 
hours. Standard errors on the fit were ± 0.7 on the mean and ± 0.5 on s.d., with RMSE 
= 0.64.
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Figure S3: Controls for PBMC-to-PBMC infection. a) PBMC with HLA-A2+ (left 
plot) or HLA-A2- (middle plot) serotype. Red line shows staining with αHLA-A2, PE 
conjugated antibody, and blue line shows staining with isotype control. αHLA-A2 
stained PBMC from the HLA-A2+ serotype (1) and HLA-A2- serotype (2) are 
compared in the rightmost plot. b) Uninfected and single positive controls. HLA-A2+
and HLA-A2- PBMC were mixed in the absence of infection (left plot). In all
experiments, the number of added HLA-A2- PBMC, which were used as donor cells, 
was approximately tenfold less than the number of HLA-A2+ target cells This was 
done to minimize transmissions with multiple infected donor cells infecting one 
target cell. To examine changes of HLA-A2 expression as a result of infection, HLA-
A2+ PBMC (middle plot) or HLA-A2- PBMC (right plot) were infected with cell-free 
NL4-3 HIV, and the number of infected cells quantified by αP24, FITC conjugated 
antibody.
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Figure S4: Relationship between viral input and number of GFP positive Rev-CEM 
reporter cells. We used Rev-CEM reporter T-cells as a target cell line. Cells of this 
line express GFP in the presence of HIV early proteins Tat and Rev. GFP is under 
viral long terminal repeat promoter regulation, and Tat leads to an increased number 
of full length transcripts from this promoter. GFP coding sequence is also flanked by 
a splice donor and splice acceptor and contains a Rev response element. The GFP 
coding sequence is therefore spliced out in the nucleus unless Rev shuttles the 
unspliced viral RNA out of the nucleus before splicing can occur, thus leading to GFP 
expression. These reporter cells enabled us to use unlabelled (hence unattenuated) 
HIV. To test for linearity of expression as a function of virus dose, 2 ml of cells at 
2x105 cells/ml were infected with serially diluted virus stock. Dashed line represents 
fit of y = 10(mlog(x)+log(b)), with slope m = 0.5, R2 >0.99. 1 ng p24 was found to contain 
8x106 HIV genomes (Methods). Means ± s.d. of replicates (n = 3).
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Figure S5: Fraction of mCherry positive cells in the MT-4mCherry cell line. a) MT-
4mCherry cells (red histogram) versus parental MT-4 cells (grey histogram). b) Dot 
plot analysis of (i) MT-4 parental line, (ii) MT-4mCherry (iii) uninfected Rev-CEM 
target cells (iv) uninfected Rev-CEM target cells mixed with MT-4mCherry donor 
cells. Numbers represent percent of cells in each quadrant. Colors from red to blue 
represent decreasing cell density.
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Figure S6: Exclusion of donor-target cell fusions. a) Flow cytometry results show 
infection of Rev-CEM cells by cell-free virus (left plot) and infected MT-4mCherry 
donors (right plot). Upper right (UR) quadrant corresponds to GFP-mCherry double 
positive cells, lower right (LR) quadrant corresponds to GFP single positive cells, and 
upper left (UL) quadrant corresponds to MT-4mCherry donor cells. b) The ratio of 
the number of fused cells on day 2 post-infection to the number of MT-4mCherry 
donors on day 0 (UR/UL). c) The ratio of fused cells on day 2 to GFP single positive 
cells on day 2 (UR/LR). Squares are mean ± s.d. of three consecutive independent 
inter-day experiments. 
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Figure S7: Drug sensitivity of HIV transmission from cocultured infected donor cells 
versus cell-free virus. Cells were infected with no virus, cell-free HIV or infectedMT-
4mCherry donor cells for 2 days and shown are flow cytometry plots of 5x105 cells 
with GFP versus mCherry fluorescence. Numbers are percent GFP positive Rev-CEM 
cells. i) uninfected Rev-CEM target cells before infection, ii) Rev-CEM cells infected 
with cell-free HIV day 2 post-infection, iii) uninfected MT-4mCherry donors + Rev-
CEM targets on day 0, iv) uninfected MT-4mCherry donors + Rev-CEM targets on 
day 2. v) infected MT-4mCherry donors + Rev-CEM targets on day 0, vi) Infected 
MT-4mCherry donors + Rev-CEM targets on day 2, vii-xi) effect of TFV on day 2 
post-infection when infection source is coculture with infected MT-4mCherry donors. 
xii-xvi) effect of TFV on day 2 post-infection when infection source is cell-free HIV. 
The fraction of MT-4mCherry donors was 1% on day 0 for control and infected MT-
4mCherry cells. The reduction in the fraction of infected donor cells on day 2 is 
consistent with cell death of HIV infected cells. 
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Figure S8: Drug sensitivity of cell-to-cell transmission from PBMC or Rev-CEM 
donors. a) FACS plots of 1.5x106 Rev-CEM target cells 2 days post-infection. Top 
row: infection source is infected PBMC donors with donor to target ratio of 1:50. 
Bottom row: infection source is cell-free virus. X-axis is 535 nm fluorescence (GFP 
specific), y-axis is 590 nm (auto-fluorescence). Numbers are percent GFP positive 
cells. b) Quantified transmission index for the infection of Rev-CEM target cells by 
infected PBMC donors (red squares), infected Rev-CEM donors (green squares), or 
cell-free virus (blue squares). Targets were Rev-CEM in all cases. Lines are guides 
for the eye. To differentiate between Rev-CEM donors and targets, targets were 
labeled with mCherry. Left graph is fusion uncorrected data, right graph shows fusion 
subtracted data, with fraction of fusions for each EFV concentration from Fig. S6c. 
Averages ± s.d. of three consecutive independent inter-day experiments. 
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Figure S9: Decrease in drug sensitivity in coculture infection was not due to factors 
secreted by donor cells. To check whether infected cells in coculture might be 
secreting cytokines or other molecules that could modify the susceptibility of target 
cells to infection, we performed infections in transwell chambers, where infected MT-
4mCherry donor cells were physically separated from the target cells, but molecule 
and virus exchange between compartments could occur. 5x105 Rev-CEM target cells 
were infected for 2 days by either coculture with 2x103 infected MT-4mCherry donor 
cells, or by cell-free virus generated by 2x105 MT-4mCherry donor cells across a 
membrane of a Corning HTS Transwell 24-well plate (polycarbonate, 0.4 μm pore 
size, cat# 3396). After 2 days of infection, 5x105 cells were analyzed for GFP 
expression by flow cytometry and fusions excluded. No mCherry positive cells or 
fusions were detected in infection across the transwell, indicating that infection 
occurred by diffusion of cell-free virus alone. Red squares: coculture. Blue Squares: 
infection across transwell barrier. Lines are guides for the eye. Means ± s.d. of three 
consecutive independent inter-day experiments. Transwell infection maintained the 
higher sensitivity of cell-free infection to drug, indicating that the donor cells are not 
secreting factors that can decrease drug sensitivity. 
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Figure S10: Two-peaked Poisson distribution results in closest fit for the number of 
infectious units transmitted in coculture. Fits of two-peaked Poisson (black line), 
single peaked Poisson (green line), and log-normal distributions (blue line) of m to 
the experimental data. Left panel shows fits for TFV, right panel shows fits for EFV. 
RMSE: Root mean squared error. df: Degrees of freedom in fit.
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Figure S11: Simulated effect of desynchronization of viral reproductive cycles on 
infection growth rate. For each of 100 individual input donor cells at day 0, we 
calculated the number of total cells infected at each time point tn = nτ, where n is an 
integer and τ is the average virus cycle length, experimentally determined to be 1.7 
days with a CVτ (s.d./mean) of 0.2 (Fig. S2). Each infected cell at tn generated Rk new 
infected cells at tn+1, where R is the replication ratio and k is a random variable from a 
normal distribution with μ = 1 and σ = μCVτ. Negative numbers of k, or k greater 
than the number of elapsed days (since virus cycles cannot be shorter than one day), 
were excluded. The sum of infected cells for each time point was divided by the 
number of input infected cells to obtain the fold change for that time point, and used 
as the number of donor cells for the next time point. Plot is for R = 2. Fold change in 
infected cells as a function of elapse time is shown for infection where simulated CV 
values were 0 (synchronized, black), 0.2 (experimentally observed, red), 0.5 (green), 
1 (magenta), and 2 (cyan).
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Figure S12: Fold change in the number of infected cells with time in individual 
independent inter-day experiments. Drug conditions were: no drug, 100 μM TFV, and 
Cmax (10 μM EFV, 2 μM TFV, and 10 μM FTC). Dashed lines represent fits of the 
equation Ik = I0Rk for each drug condition. Replication ratios fit from the data were: 
Experiment 1: Rno drug= 63, RTFV= 2.2, RCmax= 0.89. Experiment 2: Rno drug= 60, RTFV= 
2.5, RCmax= 0.97. Experiment 3: Rno drug= 70, RTFV = 2.7, RCmax= 0.99. Mean RCmax
was not significantly different from 1 (p = 0.24) but slightly lower than 1 in all 
experiments.
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Figure S13: Data used to calculate RTFVCellFree and RCmaxCellFree. Ratios were calculated 
using Eq. (3.7) (supplementary theory, Section 3). To find parameter values to 
calculate the theoretical cell-free infection ratios, we measured the half-life of virus 
producing cells (a), the drug effect on a single round of cell-free infection (b), the 
replication ratio without drug (Fig. 3a), and the virus replication cycle time (Fig. S2). 
a) Average infected Rev-CEM half-life. 1000 GFP positive Rev-CEM cells were 
mixed with 2x106 uninfected CEM-ss parental non-reporter cells  and incubated for 2 
days with varying concentrations of TFV. We assumed that under these conditions, 
few new Rev-CEM cells should be infected in the first infection cycle since any virus 
would be adsorbed by the large number of uninfected CEM-ss cells. This assumption 
is validated as increasing TFV concentrations did not change the number of GFP 
positive cells at day 2, indicating that negligible new infection of Rev-CEM targets 
occurred. Therefore, the difference between the number of GFP positive cells on day 
0 versus day 2 post mixing is almost entirely because of HIV mediated cell death of 
infected cells during the incubation period after mixing. Graph shows the number of 
remaining GFP positive cells 2 days post mixing as a fraction of input, averaged over 
three inter-day experiments. The fraction of GFP positive cells averaged across drug 
concentrations was 0.4 ± 0.01, which translates to an average half-life of 1.5 ± 0.04 
days (average ± s.d.). b) Effect of 100 μM TFV and Cmax on a single cycle of cell-
free virus infection. Mean ± s.d. (n = 3), with 106 cells collected per sample by FACS. 
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Figure S14: Representative individual infection chains. The number of newly
infected cells was approximated as a random number from a Poisson distribution with 
a mean defined by the experimentally observed replication ratio for Cmax. The 
probability of mutation if a new infection occurred was calculated as 0.29 (Methods). 
No fitness benefit or cost was assigned to individual mutations. Each infection chain 
arose with an input of one infected cell. In infection chains g and i, the input cell did 
not survive beyond the first infection cycle and caused no new infections. In infection 
chain a, the input cell infected one additional cell, but this infection did not lead to a 
mutation. The rest of the infection chains show more extensive infection but 
nevertheless terminate. Blue x’s denote total infected cells, green squares denote the 
newly infected cells, and red circles denote the total number of mutations at each time 
point. The blue line connects the number of total infected cells and is a guide for the 
eye. Mutations could either be newly generated or carried over from the previous 
infection cycle if the mutated cell survived (Methods). Division at each time point of 
the sum of infected cells by the sum of mutations from all overlapping infection 
chains is presented as the bottom graph in Fig. 3b. 
N
um
be
r 
in
fe
ct
ed
To
ta
l m
ut
at
io
ns
Day
Number total infected Number new infected Number total mutationsX
a b c
d fe
g ih
SUPPLEMENTARY INFORMATIONRESEARCHdoi:10.1038/nature10347
WWW.NATURE.COM/NATURE | 14
Sigal et al. supplementary theory
1 Relation of the number of transmitted viruses to drug
sensitivity-deterministic case
1.1 Result
We define the transmission index (TX) as the fraction of cells infected in the presence of drug
divided by the fraction of cells infected in the absence of drug. Below we show that
TX =
Id
I
=
1− e−rλ/f(d)
1− e−rλ =
1− e−m/f(d)
1− e−m . (1.1)
Variables and parameters:
• I = the fraction of infected target cells without drug.
• Id = the fraction of infected cells in the presence of drug.
• r = the probability of a single virus infecting a cell.
• λ = the number of viruses entering one cell.
• m = the number of infectious units rλ.
• d = drug concentration.
• f(d) = the fold reduction of r by drug concentration d.
1.2 Model of infection
When the fraction of infected target cells (I) is low relative to the total target cell population (T ),
I is a product of T and the probability that each target cell is infected:
I = T · Prob (infection per cell). (1.2)
The probability that no infection occurs per virus is 1−r. We assume that the infection probability
per virus is independent of other virus infections. Hence given λ viruses contacting a single cell,
the probability that none of the viruses infect is
Prob (no infection by λ viruses) = (1− r)λ. (1.3)
Therefore, the probability of successful infection with λ viruses per cell is 1− (1− r)λ and the total
number of infected cells is
I = T (1− (1− r)λ). (1.4)
1
SUPPLEMENTARY INFORMATIONRESEARCHdoi:10.1038/nature10347
WWW.NATURE.COM/NATURE | 15
1.3 Parameter values
Values for parameters above were measured in our experimental system for cell-free virus infection:
Table 1: Experimentally found quantities for cell-free virus infection
Quantity Description Found by Value
V number of input virus genomes Abbott qPCR 1010
I1 number infected cells flow cytometry 104
T 2 number target cells flow cytometry 106
r3 probability of infection I/V 10−6
λ4 number viruses per cell V/T 104
1.4 Model of infection with drug
Anti-HIV drug classes such as reverse transcriptase inhibitors, integrase inhibitors, and fusion
inhibitors, interfere with the virus life cycle before successful infection. Therefore, they reduce
infection frequency. These classes are considered here:
r → r
f(d)
. (1.5)
The effect of infection inhibiting drugs on the number of infected cells is
I = T (1− (1− r/f(d))λ). (1.6)
The ratio of the number of infected cells with drug to the number of infected cells without drug
is therefore
TX =
Id
I
=
T (1− (1− r/f(d))λ)
T (1− (1− r)λ) =
1− (1− r/f(d))λ
1− (1− r)λ . (1.7)
Since it is known experimently that r  1, we can use the approximation 1−x ≈ e−x, |x|  1,
to rewrite Eq.(1.9) as
TX ≈ 1− e
−(r/f(d))λ
1− e−rλ . (1.8)
1Measured at the end of a 2 day experiment. Since the virus cycle time in our experimental system was on average
1.7 days, two days will capture the majority of infected cells without substantial infected cell death.
2Measured at the end of a 2 day experiment. This is the total number of infectable cells and includes infected
cells, though latter is a negligible part of the total.
3Possible reasons that an input virus may not infect a cell and thus decrease r include virus degradaton or loss of
infectivity before reaching an infectable cell, the virus random walk never coming in contact with an infectable cell,
more than one virus needed to infect a cell, and the virus failing to complete essential intracellular infection steps
such as reverse transcription and integration.
4This is an upper estimate, the maximum number of viruses available per cell. The number of viruses actually
entering each cell will be lower.
2
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1.5 Limiting cases
For cell-free virus infection at the dilution shown in Table 1, rλ 1. At this limit, we can use the
approximation ex ≈ 1 + x for |x|  1 to arrive at
TX ≈ rλ/f(d)
rλ
= 1/f(d). (1.9)
Other limiting cases can be found by using the expansions ex ≈ 1 + x for |x|  1 and e−x ≈ 0
for |x|  1, and the definition rλ ≡ m. These are listed below
• m/f(d) 1 =⇒ TX ≈ 1.
• m 1 =⇒ TX ≈ 1− e−m/f(d).
• m 1, m/f(d) 1 =⇒ TX ≈ m/f(d).
2 Relation of the number of transmitted viruses to drug
sensitivity-stochastic case
The number of viruses, λ, is more realistically treated as a random variable sampled from a distri-
bution. Let p(λ) be that distribution. Then the observed TX is the ratio of the averages
T¯X(f(d)) =
∫
(1− (1− r/f(d))λ)p(λ)dλ∫
(1− (1− r)λ)p(λ)dλ . (2.1)
Here we assumed that the drug does not affect the distribution and that λ varies continuously
(in the discrete case the integral is replaced by a sum). Using the normalization condition for
the probability distribution function
∫
p(λ)dλ = 1 we can be further simplify the expression for
T¯X(f(d)) as follows:
T¯X(f(d)) =
1− ∫ (1− r/f(d))λp(λ)dλ
1− ∫ (1− r)λp(λ)dλ . (2.2)
An approximate value can be found in the limit rλ  1. Expanding (1 − r)λ in r around 0 up to
first order,
(1− r)λ = 1− rλ+O(r2). (2.3)
and substituting back into T¯X(f(d)) we get
T¯X(f(d)) =
1− ∫ (1− rλ/f(d))p(λ)dλ
1− ∫ (1− rλ)p(λ)dλ =
∫
(rλ/f(d))p(λ)dλ∫
rλp(λ)dλ
=
1
f(d)
. (2.4)
which reproduces our result in equation 1.10 above. In the general case T¯X(f(d)) can be compared
numerically with the experimentally found dependence. However, in some special cases an exact
analytical expression for T¯X can be found. One of these is if λ is sampled from a Poisson distribution
with mean µ, that is
pµ(λ) =
µλe−µ
λ!
. (2.5)
3
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Accordingly the probability for infection with λ viruses is
I(λ;µ, r) = T (1− (1− r)λ)µ
λe−µ
λ!
. (2.6)
Summing over λ we get
I(µ, r) = T
∞∑
λ=0
I(λ;µ, r) = T
∞∑
λ=0
(1− (1− r)λ)µ
λe−µ
λ!
. (2.7)
Expanding the parenthesis and noting that
∑∞
λ=0 µ
λe−µ/λ! = 1 we arrive at
I(µ, r) = (1− e−µ
∞∑
λ=0
((1− r)µ)λ
λ!
)T. (2.8)
Finally, recognizing that
∑∞
n=0 z
n/n! = ez we arrive at our key result:
I(µ, r) = (1− e−µe(1−r)µ)T = (1− e−rµ)T. (2.9)
Accordingly TX takes the same form as the deterministic solution
TXµ(f(d)) =
Id
I
=
1− e−(r/f(d))µ
1− e−rµ . (2.10)
Note that this result is valid for both the drug classes that reduce infection frequency and burst
size since in both cases the drug effect reduces the mean of the distribution, µ→ µ/f(d).
3 Calculating predicted infection behavior of cell-free virus
in the presence of drugs
Whether infection expands or terminates depends on the replication ratio R [1,2] which we define
as
R = k
√
Ik
I0
, (3.1)
where Ik is the number of infected cells at infection cycle k, and I0 is the number of infected cells
at the start of the experiment. If R > 1, the infection expands. If R < 1, the infection eventually
terminates. We wish to obtain Rdfree, the replication ratio for cell-free virus in the presence of
drug. However, infection for multiple infection cycles is a combination of cell-free and cell-to-cell
transmission so that Rdfree cannot be measured. R
d
free can still be predicted if its relationship to
R, the measurable replication ratio without drug, and ffree(d), the drug effect per cell-free virus
infection cycle, can be established. We derive that relationship below.
In the case where the number of uninfected cells is non-limiting (approximated in our experi-
ments by keeping the fraction of infected cells low), the number of infected cells in the (k+1)-th
cycle of infection depends both on the number of newly infected cells, infected by cells from the
k-th cycle, and the number of infected cells remaining from the k-th cycle.
Ik+1 = Inewk+1 + I
leftover
k+1 . (3.2)
4
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The number of newly infected cells is determined by ρ, where ρ ∝ rλ [1]:
Inewk+1 = ρIk. (3.3)
For simplicity, we assume that ρ is identical for any two consecutive cycles. The number of infected
cells left over from the k-th cycle is:
I leftoverk+1 = 2
− τt1/2 Ik. (3.4)
Where τ is the virus cycle length, and t1/2 is the infected cell half-life after it starts producing
virus. Therefore, the equation for the number of infected cells in the (k+1)-th cycle as a function
of the number of infected cells in the k-th cycle is
Ik+1 = ρIk + 2
− τt1/2 Ik. (3.5)
The first term takes into account the rate of addition of newly infected cells and the second term
takes into account the number of cells left over from the previous virus infection cycle. Eq.(3.5)
can be easily solved for Ik as a function of the initial infected cells at start I0. If q = ρ+ 2
− τt1/2 , it
can be seen that I1 = I0q, I2 = I1q = I0qq = I0q2, Ik = I0qk. We therefore obtain
Ik = I0
(
ρ+ 2
− τt1/2
)k
. (3.6)
Eq (3.6) can be used to fit infection dynamics with no drug to obtain ρ. To find the predicted
infection replication rate for cell-free virus with drug, we use Eq (1.5) or Eq (1.6) and the relation
ρ ∝ rλ [1,2] to obtain ρd = ρf(d) , where ρd is ρ in the presence of drug. Substituting into Eq (3.6)
gives the replication rate as a function of Idk , the number of infected cells with drug at infection
cycle k, ρ, and the drug effect ffree(d):
Rdfree =
k
√
Idk
I0
=
ρ
ffree(d)
+ 2
− τt1/2 . (3.7)
Table 2 lists numerical values for the parameters appearing in Eq (3.7) and their sources.
Table 2: Values of components for Eq (3.7)
Quantity Value Found by
ρ 64 Fit of infection without drug to Eq (3.6)
ffree(TFV ) 1x102 1/TX for 100µM TFV for drug stock used in experiment
ffree(Cmax) 5x102 1/TX for 10µM EFV + 2µM TFV + 10 µM FTC for drug stocks used in experiment
τ 1.7 Measured, Fig. S4
t1/2 1.5 Measured, Fig. S13
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